Scope Fluidics Spolka Akcyjna (WAR:SCP) EPS without NRI: zł-17.10 (TTM As of Mar. 2026)


WAR:SCP Scope Fluidics Spolka Akcyjna WAR:SCP
50 GF Score
Price zł122.00
GF Value zł129.17
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Scope Fluidics Spolka Akcyjna EPS without NRI?

Scope Fluidics Spolka Akcyjna WAR:SCP -0.49% 50 EPS without NRI is zł-17.10 as of Mar. 2026. GuruFocus rates WAR:SCP with a GF Score™ of 50/100 and a GF Value™ of zł129.17 (Fairly Valued). The stock has 4 warning signs investors should review. Among 160 Medical Diagnostics & Research companies, Scope Fluidics Spolka Akcyjna ranks worse than 99.38% on this metric.

Scope Fluidics Spolka Akcyjna's earnings per share without non-recurring items for the three months ended in Mar. 2026 was zł-4.31. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was zł-17.10.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -112.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -31.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Scope Fluidics Spolka Akcyjna's EPS without NRI or its related term are showing as below:

WAR:SCP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -112.2   Med: -21.6   Max: 16.1
Current: -112.2

During the past 10 years, Scope Fluidics Spolka Akcyjna's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 16.10% per year. The lowest was -112.20% per year. And the median was -21.60% per year.

WAR:SCP's 3-Year EPS without NRI Growth Rate is ranked worse than
99.38% of 160 companies
in the Medical Diagnostics & Research industry
Industry Median: 10.75 vs WAR:SCP: -112.20

Scope Fluidics Spolka Akcyjna's EPS (Diluted) for the three months ended in Mar. 2026 was zł-4.25. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was zł-16.97.

Scope Fluidics Spolka Akcyjna's EPS (Basic) for the three months ended in Mar. 2026 was zł-4.25. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was zł-14.86.


Scope Fluidics Spolka Akcyjna  (WAR:SCP) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Scope Fluidics Spolka Akcyjna EPS without NRI Related Terms


Scope Fluidics Spolka Akcyjna EPS without NRI Historical Data

* Premium members only.

The historical data trend for Scope Fluidics Spolka Akcyjna's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scope Fluidics Spolka Akcyjna EPS without NRI Chart

Scope Fluidics Spolka Akcyjna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.36 -1.79 -7.16 -7.15 -17.15

Scope Fluidics Spolka Akcyjna Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.14 -3.14 -4.17 -5.48 -4.31

WAR:SCP vs TMO, DHR, IDXX: EPS without NRI Comparison

For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scope Fluidics Spolka Akcyjna PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Scope Fluidics Spolka Akcyjna's PE Ratio without NRI falls into.


WAR:SCP
50GF Score
Scope Fluidics Spolka Akcyjna WAR:SCP
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scope Fluidics Spolka Akcyjna EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-17.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of zł-17.10 mean?
Scope Fluidics Spolka Akcyjna (WAR:SCP) has a EPS without NRI of zł-17.10 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. According to the industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #159 out of 160 companies in the Medical Diagnostics & Research industry, placing it in the top 99.4%.
Is Scope Fluidics Spolka Akcyjna's EPS without NRI too high?
Scope Fluidics Spolka Akcyjna's current EPS without NRI is zł-17.10. Based on the distribution chart, Scope Fluidics Spolka Akcyjna ranks #159 out of 160 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's EPS without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #159 out of 160 companies for EPS without NRI. This places Scope Fluidics Spolka Akcyjna in the lower half of its industry. The industry median EPS without NRI is 10.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.75, based on 160 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scope Fluidics Spolka Akcyjna's current EPS without NRI is zł-17.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna (WAR:SCP) is currently considered Fairly Valued. The stock's GF Value™ is zł129.17, compared to a current price of zł122.00 — trading 5.6% below its estimated fair value. The current EPS without NRI is zł-17.10. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (WAR:SCP), the current EPS without NRI is zł-17.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scope Fluidics Spolka Akcyjna (WAR:SCP) Overvalued in 2026?

Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be undervalued. The current stock price of zł122.00 is trading 5.6% below its estimated GF Value™ of zł129.17. GuruFocus considers Scope Fluidics Spolka Akcyjna to be Fairly Valued.

Key valuation signals for WAR:SCP:

  • EPS without NRI: zł-17.10
  • GF Value™: zł129.17 vs. price of zł122.00 (5.6% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the WAR:SCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scope Fluidics Spolka Akcyjna Business Description

Address Duchnicka 3, Build 16, Entrance A, Warsaw, POL, 01-796
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
50GF Score

Get the complete analysis for WAR:SCP

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł122.00
Price
zł129.17
GF Value